Pfizer Global Partnerships

News

Pfizer Strikes Deal With China's 3SBio

Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.

Reuters on MSN · 1d

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Yicai Global · 1d

China’s 3SBio Soars on Granting Pfizer New Cancer Drug Rights in USD6 Billion Deal

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment, according to the agreement announced yesterday. The deal also includes an option for Pfizer to acquire commercialization rights in China.

BioSpace1d

Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer's Turnaround Story Is Stronger Than You Think

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

The Manila Times12h

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

BioSpace1d

Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pharm Exec2d

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy ...

Yahoo Finance27d

Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

pharmaphorum8d

Pfizer vaults into sickle cell market as GBT deal confirmed

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

News921d

Pfizer donates $750,000 to tribal health centers in Oklahoma

Global pharmaceutical company Pfizer Inc. is donating $750,000 to ... praised the donation as a sign of progress in public-private partnerships. “I am honored to work alongside Pfizer and ...

BusinessMirror28d

Pfizer reaffirms commitment to healthcare innovation on its 70th year in the Philippines

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...

Zacks Investment Research on MSN1d

Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results